ArticleBMJ open2025

Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design.

Jiaxi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.